{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:59:16Z","timestamp":1792144756236,"version":"4.4.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"\n Importance<\/jats:title>\n There is an urgent need for algorithm trials that address treatment steps in schizophrenia sequentially. Moreover, there is a debate about whether clozapine should be used after 1 failed antipsychotic drug trial.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate whether switching to clozapine is effective in patients with first-episode psychosis (FEP) who have not responded to 1 previous antipsychotic drug.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a sequential, assessor-blind trial with 2 randomizations conducted across 7 centers in China from February 2019 to October 2022. Included were individuals aged 16 to 45 years and with FEP (schizophrenia, schizophreniform disorder, or schizoaffective disorder). In phase 1, patients with FEP were randomized to receive oral olanzapine, risperidone, amisulpride, aripiprazole, or perphenazine for 8 weeks. In phase 2, nonresponders were rerandomized to receive olanzapine, amisulpride, or clozapine for another 8 weeks. Responders entered a 1-year naturalistic follow-up. Study data were analyzed from February to August 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Specific antipsychotic drugs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were as follows (1) symptomatic response, defined as the proportion of patients achieving a greater than or equal to 40% reduction in Positive and Negative Syndrome Scale (PANSS) total score and (2) time to all-cause discontinuation, defined as discontinuation of antipsychotic drugs for any reason.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 762 participants were randomized, and 654 (mean [SD] age, 26.9 [7.5] years; 328 male [50.2%]) were eligible for the study. Of the eligible participants, 556 (85.4%) completed phase 1, and 359 (55.1%) responded to treatment. Response rates were 60.5% (78 of 129) for olanzapine, 63.4% (83 of 131) for risperidone, 61.8% (81 of 131) for amisulpride, 44.3% (58 of 131) for aripiprazole, and 45.7% (59 of 129) for perphenazine (\u03c7\n 2<\/jats:sup>\n \u2009=\u200918.3;\n P<\/jats:italic>\n \u2009=\u2009.001). In phase 2, 111 nonresponders were rerandomized (41 taking olanzapine, 38 taking amisulpride, and 32 taking clozapine). A total of 92 patients (82.9%) completed phase 2, and the following achieved a response: 13 (31.7%) taking olanzapine vs 17 (44.7%) taking amisulpride and 20 (62.5%) taking clozapine (\u03c7\n 2<\/jats:sup>\n \u2009=\u20096.9;\n P<\/jats:italic>\n \u2009=\u2009.03).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The majority of patients with FEP responded to an initial antipsychotic drug trial, with risperidone and amisulpride being superior to aripiprazole and perphenazine. In those who initially did not respond to antipsychotic treatment, clozapine was more efficacious than olanzapine and amisulpride based on the PANSS ratings criteria outcome. This study provides some evidence for clinicians to consider regarding use of clozapine as the next sequential treatment after patients have failed an adequate trial with 1 of the more traditional antipsychotics.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03510325<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.0086","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:00:30Z","timestamp":1773241230000},"page":"570","source":"Crossref","is-referenced-by-count":11,"title":["Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis"],"prefix":"10.1001","volume":"83","author":[{"given":"Xuan","family":"Li","sequence":"first","affiliation":[{"name":"Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China"},{"name":"Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolin","family":"Zhai","sequence":"additional","affiliation":[{"name":"Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Smith","sequence":"additional","affiliation":[{"name":"Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York"},{"name":"Department of Psychiatry, New York University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China"},{"name":"Department of Psychiatry, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing AnDing Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Seventh People\u2019s Hospital of Hangzhou, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The First Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoufu","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Seventh People\u2019s Hospital of Dalian, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Feng","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhao","family":"Gao","sequence":"additional","affiliation":[{"name":"Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuke","family":"Dong","sequence":"additional","affiliation":[{"name":"Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China"},{"name":"Department of Psychiatry, Huashan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiming","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Xiang","sequence":"additional","affiliation":[{"name":"Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Illinois Chicago, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaida","family":"Jiang","sequence":"additional","affiliation":[{"name":"Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China"},{"name":"Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai JiaoTong University School of Medicine, Shanghai, China"},{"name":"Shanghai Clinical Research Center for Mental Health, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengtang","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China"},{"name":"Department of Psychiatry, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai JiaoTong University School of Medicine, Shanghai, China"},{"name":"Shanghai Clinical Research Center for Mental Health, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"yoi260005r1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.schres.2024.02.035","article-title":"Response rates to sequential trials of antipsychotic medications according to algorithms or treatment guidelines in psychotic disorders: a systematic review and meta-analysis.","volume":"268","author":"O\u2019Donoghue","year":"2024","journal-title":"Schizophr Res"},{"issue":"9","key":"yoi260005r2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","article-title":"How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis.","volume":"27","author":"Zhu","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"yoi260005r3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis.","volume":"220","author":"Siskind","year":"2022","journal-title":"Br J Psychiatry"},{"key":"yoi260005r4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.schres.2022.11.010","article-title":"The prognosis of schizophrenia: a systematic review and meta-analysis with meta-regression of 20-year follow-up studies.","volume":"250","author":"Molstrom","year":"2022","journal-title":"Schizophr Res"},{"issue":"6","key":"yoi260005r5","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.4088\/JCP.13m08606","article-title":"The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis.","volume":"75","author":"Jordan","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"yoi260005r6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia.","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"6","key":"yoi260005r7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/schbul\/sbaa060","article-title":"Clozapine combination and augmentation strategies in patients with schizophrenia\u2014recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) working group.","volume":"46","author":"Wagner","year":"2020","journal-title":"Schizophr Bull"},{"issue":"4","key":"yoi260005r8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/acps.12700","article-title":"The impact of clozapine on hospital use: a systematic review and meta-analysis.","volume":"135","author":"Land","year":"2017","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"yoi260005r9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors.","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"issue":"2","key":"yoi260005r10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years.","volume":"45","author":"Vermeulen","year":"2019","journal-title":"Schizophr Bull"},{"key":"yoi260005r11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.schres.2019.12.009","article-title":"Dose and safety concerns of clozapine: worldwide package inserts need revisions.","volume":"216","author":"de Leon","year":"2020","journal-title":"Schizophr Res"},{"issue":"2","key":"yoi260005r12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ps.201500324","article-title":"Clozapine for schizophrenia: state variation in evidence-based practice.","volume":"67","author":"Olfson","year":"2016","journal-title":"Psychiatr Serv"},{"issue":"6","key":"yoi260005r13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation.","volume":"201","author":"Howes","year":"2012","journal-title":"Br J Psychiatry"},{"issue":"2","key":"yoi260005r14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.sjpmh.2024.06.001","article-title":"Clozapine use in the first 2 years after first-episode psychosis in a real-world clinical sample.","volume":"18","author":"Pechu\u00e1n","year":"2025","journal-title":"Span J Psychiatry Ment Health"},{"issue":"11","key":"yoi260005r15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.","volume":"72","author":"Agid","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"yoi260005r16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine vs olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"10","key":"yoi260005r17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a 3-phase switching study.","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"yoi260005r18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1055\/a-2110-4259","article-title":"Effects of early clozapine treatment on remission rates in acute schizophrenia (the EARLY trial): protocol of a randomized-controlled multicentric trial.","volume":"56","author":"Wagner","year":"2023","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"yoi260005r19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/acps.12954","article-title":"Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis.","volume":"138","author":"Okhuijsen-Pfeifer","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"yoi260005r20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.schres.2020.11.010","article-title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: rationale and trial design.","volume":"230","author":"Li","year":"2021","journal-title":"Schizophr Res"},{"issue":"1","key":"yoi260005r21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5.","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr Res"},{"key":"yoi260005r22","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi260005r23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"3","key":"yoi260005r24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0920-9964(92)90003-N","article-title":"Reliability and validity of a depression rating scale for schizophrenics.","volume":"6","author":"Addington","year":"1992","journal-title":"Schizophr Res"},{"key":"yoi260005r26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"4","key":"yoi260005r27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The Barnes Akathisia Rating Scale\u2013revisited.","volume":"17","author":"Barnes","year":"2003","journal-title":"J Psychopharmacol"},{"issue":"4","key":"yoi260005r28","first-page":"781","article-title":"Abnormal Involuntary Movement Scale (AIMS).","volume":"24","author":"Abnormal Involuntary Movement Scale (AIMS)","year":"1988","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"yoi260005r29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The Arizona Sexual Experience Scale (ASEX): reliability and validity.","volume":"26","author":"McGahuey","year":"2000","journal-title":"J Sex Marital Ther"},{"key":"yoi260005r30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4088\/JCP.13049su1c.02","article-title":"Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application.","volume":"75","author":"Leucht","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"yoi260005r31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/schbul\/sbp124","article-title":"Should the PANSS be rescaled?","volume":"36","author":"Obermeier","year":"2010","journal-title":"Schizophr Bull"},{"issue":"10","key":"yoi260005r32","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications.","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"yoi260005r33","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/394896","article-title":"Randomized controlled trial of clozapine and CBT for first-episode psychosis with enduring positive symptoms: a pilot study.","volume":"2011","author":"Edwards","year":"2011","journal-title":"Schizophr Res Treatment"},{"issue":"2","key":"yoi260005r34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00213-007-0872-2","article-title":"How effective is it to sequentially switch among olanzapine, quetiapine and risperidone: a randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.","volume":"195","author":"Suzuki","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"yoi260005r35","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","article-title":"Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses.","volume":"4","author":"Zhu","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"yoi260005r37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology.","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi260005r38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S2215-0366(24)00366-3","article-title":"Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study.","volume":"12","author":"Taipale","year":"2025","journal-title":"Lancet Psychiatry"},{"issue":"9896","key":"yoi260005r39","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"yoi260005r40","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S2215-0366(22)00304-2","article-title":"The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis.","volume":"9","author":"Leucht","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"yoi260005r41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41537-019-0091-y","article-title":"Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders.","volume":"6","author":"Phahladira","year":"2020","journal-title":"NPJ Schizophr"},{"issue":"9618","key":"yoi260005r42","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"yoi260005r43","doi-asserted-by":"publisher","DOI":"10.1177\/20451253251333987","article-title":"Investigation on the factors associated with maintenance of paliperidone long-acting injection in the real-world treatment of patients with schizophrenia.","volume":"15","author":"Kang","year":"2025","journal-title":"Ther Adv Psychopharmacol"},{"key":"yoi260005r44","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.psychres.2019.01.068","article-title":"Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: results from an open-label, randomized, \u201creal world\u201d clinical trial.","volume":"273","author":"Cheng","year":"2019","journal-title":"Psychiatry Res"},{"key":"yoi260005r45","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.874705","article-title":"Risperidone induced hyperprolactinemia: from basic to clinical studies.","volume":"13","author":"Stojkovic","year":"2022","journal-title":"Front Psychiatry"},{"issue":"1","key":"yoi260005r46","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"yoi260005r47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","article-title":"Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis.","volume":"237","author":"Zhu","year":"2021","journal-title":"Schizophr Res"},{"issue":"4","key":"yoi260005r48","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00406-023-01654-2","article-title":"A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia.","volume":"274","author":"Dong","year":"2024","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"yoi260005r49","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S2215-0366(25)00025-2","article-title":"The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomized, placebo-controlled, clinical trials in acute phase schizophrenia.","volume":"12","author":"Nomura","year":"2025","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"yoi260005r50","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S2215-0366(24)00097-X","article-title":"Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland.","volume":"11","author":"Rubio","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"yoi260005r51","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S2215-0366(22)00044-X","article-title":"Long-term treatment with clozapine and other antipsychotic drugs and the risk of hematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland.","volume":"9","author":"Tiihonen","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"yoi260005r52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review.","volume":"11","author":"Wagner","year":"2021","journal-title":"Transl Psychiatry"},{"key":"yoi260005r53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.schres.2023.03.048","article-title":"A brief history of clozapine in China with a look forward.","volume":"268","author":"Ruan","year":"2024","journal-title":"Schizophr Res"},{"key":"yoi260005r25","first-page":"303","volume-title":"Encyclopedia of Psychopharmacology","author":"Padhi","year":"2010"},{"key":"yoi260005r36","unstructured":"Psychometrica. Computation of effect sizes. Accessed August 27, 2025. http:\/\/www.psychometrica.de\/effect_size.html"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2845904\/jamapsychiatry_li_2026_oi_260005_1779900176.74871.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:00:31Z","timestamp":1780498831000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2845904"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0086","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}